Tissue culture drug resistance analysis of a novel HIV-1 protease inhibitor termed PL-100 in non-B HIV-1 subtypes
- 1 September 2010
- journal article
- Published by Elsevier in Antiviral Research
- Vol. 87 (3) , 367-372
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- A comparison of HIV‐1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotypeJournal of Medical Virology, 2009
- Transmission networks of drug resistance acquired in primary/early stage HIV infectionAIDS, 2008
- PL‐100, a novel HIV‐1 protease inhibitor displaying a high genetic barrier to resistance: An in vitro selection studyJournal of Medical Virology, 2008
- The HIV-1 protease substitution K55R: a protease-inhibitor-associated substitution involved in restoring viral replicationJournal of Antimicrobial Chemotherapy, 2008
- In Vitro Antiviral Activity and Cross-Resistance Profile of PL-100, a Novel Protease Inhibitor of Human Immunodeficiency Virus Type 1Antimicrobial Agents and Chemotherapy, 2007
- Natural Polymorphisms in the Human Immunodeficiency Virus Type 2 Protease Can Accelerate Time to Development of Resistance to Protease InhibitorsAntimicrobial Agents and Chemotherapy, 2007
- Impact of Human Immunodeficiency Virus Type 1 Subtype C on Drug Resistance Mutations in Patients from Botswana Failing a Nelfinavir-Containing RegimenAntimicrobial Agents and Chemotherapy, 2006
- Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavirJournal of Medical Virology, 2005
- Biologic and Genetic Characterization of a Panel of 60 Human Immunodeficiency Virus Type 1 Isolates, Representing Clades A, B, C, D, CRF01_AE, and CRF02_AG, for the Development and Assessment of Candidate VaccinesJournal of Virology, 2005
- Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patientsJournal of Medical Virology, 2004